(MRNA) Moderna - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US60770K1079
Stock: Vaccines, Oncology, Rare, Therapeutics, MRNA
Total Rating 39
Risk 32
Buy Signal 0.35
| Risk 5d forecast | |
|---|---|
| Volatility | 92.3% |
| Relative Tail Risk | -12.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 49.82 |
| Character TTM | |
|---|---|
| Beta | 1.515 |
| Beta Downside | 2.078 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.58% |
| CAGR/Max DD | -0.31 |
EPS (Earnings per Share)
Revenue
Description: MRNA Moderna February 26, 2026
Moderna (NASDAQ: MRNA) is a U.S.-based biotechnology firm that develops messenger-RNA (mRNA) medicines across a broad therapeutic spectrum, including respiratory, latent, enteric, public-health, bacterial, oncology, and rare-disease indications.
Its vaccine portfolio now spans Spikevax (COVID-19), mRESVIA (RSV), seasonal and pandemic influenza candidates, as well as pipelines for cytomegalovirus, Epstein-Barr virus, Zika, Nipah, and Lyme disease, while its oncology arm focuses on individualized neoantigen and checkpoint-modulating therapies.
Key recent metrics show Q3 2025 revenue of $5.3 billion, up 12 % year-over-year, and a cash position of $7.2 billion, supporting continued R&D investment of $2.1 billion in 2025. The global mRNA market is projected to grow at a 14 % CAGR through 2030, driven by expanding vaccine demand and emerging therapeutic applications.
Strategic collaborations remain central to Moderna’s growth, notably its multi-year partnership with AstraZeneca on oncology mRNA candidates, a joint development agreement with Merck on rare-disease therapies, and ongoing work with the Bill & Melinda Gates Foundation on infectious-disease vaccines.
For a deeper dive, you might explore ValueRay’s analysis of MRNA.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -2.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA 12.03 > 1.0 |
| NWC/Revenue: 234.5% < 20% (prev 184.2%; Δ 50.32% < -1%) |
| CFO/TA -0.15 > 3% & CFO -1.85b > Net Income -2.82b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (392.0m) vs 12m ago 1.82% < -2% |
| Gross Margin: 14.10% > 18% (prev 0.54%; Δ 1356 % > 0.5%) |
| Asset Turnover: 14.68% > 50% (prev 22.62%; Δ -7.95% > 0%) |
| Interest Coverage Ratio: -276.6 > 6 (EBITDA TTM -2.55b / Interest Expense TTM 10.0m) |
Altman Z'' 5.00
| A: 0.37 (Total Current Assets 6.54b - Total Current Liabilities 1.99b) / Total Assets 12.34b |
| B: 0.59 (Retained Earnings 7.22b / Total Assets 12.34b) |
| C: -0.21 (EBIT TTM -2.77b / Avg Total Assets 13.24b) |
| D: 1.97 (Book Value of Equity 7.27b / Total Liabilities 3.69b) |
| Altman-Z'' Score: 5.00 = AAA |
Beneish M -1.16
| DSRI: 0.51 (Receivables 184.0m/592.0m, Revenue 1.94b/3.20b) |
| GMI: 3.85 (GM 14.10% / 54.24%) |
| AQI: 1.09 (AQ_t 0.24 / AQ_t-1 0.22) |
| SGI: 0.61 (Revenue 1.94b / 3.20b) |
| TATA: -0.08 (NI -2.82b - CFO -1.85b) / TA 12.34b) |
| Beneish M-Score: -1.16 (Cap -4..+1) = D |
What is the price of MRNA shares?
As of March 07, 2026, the stock is trading at USD 53.83 with a total of 13,934,588 shares traded.
Over the past week, the price has changed by +4.10%, over one month by +31.71%, over three months by +94.33% and over the past year by +52.88%.
Over the past week, the price has changed by +4.10%, over one month by +31.71%, over three months by +94.33% and over the past year by +52.88%.
Is MRNA a buy, sell or hold?
Moderna has received a consensus analysts rating of 3.22.
Therefor, it is recommend to hold MRNA.
- StrongBuy: 5
- Buy: 1
- Hold: 17
- Sell: 3
- StrongSell: 1
What are the forecasts/targets for the MRNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.3 | -21.5% |
| Analysts Target Price | 42.3 | -21.5% |
MRNA Fundamental Data Overview March 06, 2026
P/E Forward = 23.0415
P/S = 11.7425
P/B = 2.4128
Revenue TTM = 1.94b USD
EBIT TTM = -2.77b USD
EBITDA TTM = -2.55b USD
Long Term Debt = 590.0m USD (from longTermDebt, last quarter)
Short Term Debt = 48.0m USD (from shortTermDebt, two quarters ago)
Debt = 1.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -679.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.94b USD (22.83b + Debt 1.92b - CCE 5.80b)
Interest Coverage Ratio = -276.6 (Ebit TTM -2.77b / Interest Expense TTM 10.0m)
EV/FCF = -9.22x (Enterprise Value 18.94b / FCF TTM -2.05b)
FCF Yield = -10.84% (FCF TTM -2.05b / Enterprise Value 18.94b)
FCF Margin = -105.7% (FCF TTM -2.05b / Revenue TTM 1.94b)
Net Margin = -145.2% (Net Income TTM -2.82b / Revenue TTM 1.94b)
Gross Margin = 14.10% ((Revenue TTM 1.94b - Cost of Revenue TTM 1.67b) / Revenue TTM)
Gross Margin QoQ = 33.33% (prev 0.79%)
Tobins Q-Ratio = 1.54 (Enterprise Value 18.94b / Total Assets 12.34b)
Interest Expense / Debt = 0.42% (Interest Expense 8.00m / Debt 1.92b)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.19b (EBIT -2.77b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 6.54b / Total Current Liabilities 1.99b)
Debt / Equity = 0.22 (Debt 1.92b / totalStockholderEquity, last quarter 8.65b)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -679.0m / EBITDA -2.55b)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -679.0m / FCF TTM -2.05b)
Total Stockholder Equity = 9.36b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.31% (Net Income -2.82b / Total Assets 12.34b)
RoE = -30.15% (Net Income TTM -2.82b / Total Stockholder Equity 9.36b)
RoCE = -27.80% (EBIT -2.77b / Capital Employed (Equity 9.36b + L.T.Debt 590.0m))
RoIC = -22.98% (negative operating profit) (NOPAT -2.19b / Invested Capital 9.51b)
WACC = 9.53% (E(22.83b)/V(24.74b) * Re(10.30%) + D(1.92b)/V(24.74b) * Rd(0.42%) * (1-Tc(0.21)))
Discount Rate = 10.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Fair Price = unknown (Cash Flow -2.05b)
EPS Correlation: -66.99 | EPS CAGR: -20.73% | SUE: 0.68 | # QB: 0
Revenue Correlation: -62.50 | Revenue CAGR: -43.94% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-2.10 | Chg7d=+0.011 | Chg30d=+0.218 | Revisions Net=+5 | Analysts=10
EPS current Year (2026-12-31): EPS=-6.68 | Chg7d=+0.021 | Chg30d=+0.150 | Revisions Net=+6 | Growth EPS=+8.1% | Growth Revenue=+6.2%
EPS next Year (2027-12-31): EPS=-4.60 | Chg7d=+0.013 | Chg30d=+0.131 | Revisions Net=+4 | Growth EPS=+31.1% | Growth Revenue=+22.0%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
P/S = 11.7425
P/B = 2.4128
Revenue TTM = 1.94b USD
EBIT TTM = -2.77b USD
EBITDA TTM = -2.55b USD
Long Term Debt = 590.0m USD (from longTermDebt, last quarter)
Short Term Debt = 48.0m USD (from shortTermDebt, two quarters ago)
Debt = 1.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -679.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.94b USD (22.83b + Debt 1.92b - CCE 5.80b)
Interest Coverage Ratio = -276.6 (Ebit TTM -2.77b / Interest Expense TTM 10.0m)
EV/FCF = -9.22x (Enterprise Value 18.94b / FCF TTM -2.05b)
FCF Yield = -10.84% (FCF TTM -2.05b / Enterprise Value 18.94b)
FCF Margin = -105.7% (FCF TTM -2.05b / Revenue TTM 1.94b)
Net Margin = -145.2% (Net Income TTM -2.82b / Revenue TTM 1.94b)
Gross Margin = 14.10% ((Revenue TTM 1.94b - Cost of Revenue TTM 1.67b) / Revenue TTM)
Gross Margin QoQ = 33.33% (prev 0.79%)
Tobins Q-Ratio = 1.54 (Enterprise Value 18.94b / Total Assets 12.34b)
Interest Expense / Debt = 0.42% (Interest Expense 8.00m / Debt 1.92b)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.19b (EBIT -2.77b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 6.54b / Total Current Liabilities 1.99b)
Debt / Equity = 0.22 (Debt 1.92b / totalStockholderEquity, last quarter 8.65b)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -679.0m / EBITDA -2.55b)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -679.0m / FCF TTM -2.05b)
Total Stockholder Equity = 9.36b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.31% (Net Income -2.82b / Total Assets 12.34b)
RoE = -30.15% (Net Income TTM -2.82b / Total Stockholder Equity 9.36b)
RoCE = -27.80% (EBIT -2.77b / Capital Employed (Equity 9.36b + L.T.Debt 590.0m))
RoIC = -22.98% (negative operating profit) (NOPAT -2.19b / Invested Capital 9.51b)
WACC = 9.53% (E(22.83b)/V(24.74b) * Re(10.30%) + D(1.92b)/V(24.74b) * Rd(0.42%) * (1-Tc(0.21)))
Discount Rate = 10.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Fair Price = unknown (Cash Flow -2.05b)
EPS Correlation: -66.99 | EPS CAGR: -20.73% | SUE: 0.68 | # QB: 0
Revenue Correlation: -62.50 | Revenue CAGR: -43.94% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-2.10 | Chg7d=+0.011 | Chg30d=+0.218 | Revisions Net=+5 | Analysts=10
EPS current Year (2026-12-31): EPS=-6.68 | Chg7d=+0.021 | Chg30d=+0.150 | Revisions Net=+6 | Growth EPS=+8.1% | Growth Revenue=+6.2%
EPS next Year (2027-12-31): EPS=-4.60 | Chg7d=+0.013 | Chg30d=+0.131 | Revisions Net=+4 | Growth EPS=+31.1% | Growth Revenue=+22.0%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)